Evidence map›Paper›PMID 38099861›Full record

ArticleHepatology communications2024

Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death.

Neil Halliday, Nadia Eden, Henry Somers, Niall Burke, Hiroshi Silva, Camila Gx Brito, Andrew Hall, Alberto Quaglia, Siobhan O Burns, David M Lowe and 1 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Neil HallidayUCL Institute for Liver and Digestive Health, University College London, London, UK.ORCID 0000-0001-8220-9139
Nadia EdenUCL Institute for Liver and Digestive Health, University College London, London, UK.
Henry SomersUCL Institute for Liver and Digestive Health, University College London, London, UK.
Niall BurkeUCL Institute for Liver and Digestive Health, University College London, London, UK.
Hiroshi SilvaDepartment of Cellular Pathology, Royal Free London NHS Foundation Trust, London, UK.
Camila Gx BritoDepartment of Cellular Pathology, Royal Free London NHS Foundation Trust, London, UK.
Andrew HallSheila Sherlock liver centre, Royal Free London NHS Foundation Trust, London, UK.
Alberto QuagliaUCL Institute for Liver and Digestive Health, University College London, London, UK.
Siobhan O BurnsInstitute of Immunity and Transplantation, University College London, UK.ORCID 0000-0002-3356-9506
David M LoweInstitute of Immunity and Transplantation, University College London, UK.
Douglas ThorburnUCL Institute for Liver and Digestive Health, University College London, London, UK.
Royal Free London NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommon variable immunodeficiency disorder (CVID) manifests with recurrent infections and inflammatory complications, including liver disease. We report the clinical features, natural history, and outcomes of patients with CVID-related liver disease (CVID-rLD) from a tertiary immunology and hepatology center.

methodsTwo hundred eighteen patients were identified; CVID-rLD was defined by persistently abnormal liver function tests or evidence of chronic liver disease (CLD) or portal hypertension (PHTN) by radiological or endoscopic investigation, after exclusion of other causes. Patients with CVID-rLD were investigated and managed following a joint pathway between immunology and hepatology services. Data, including clinical parameters, investigations, and outcomes, were retrospectively collected.

resultsA total of 91/218 (42%) patients had evidence of CVID-rLD, and 40/91 (44%) had PHTN. Patients with CVID-rLD were more likely to have other noninfectious complications of CVID (85/91, 93.4% vs. 75/127, 59.1%, p<0.001) including interstitial lung disease, gut disease, and autoimmune cytopenias. Nodular regenerative hyperplasia (NRH) was identified in 63.8% of liver biopsies, and fibrosis in 95.3%. Liver stiffness measurements (LSMs) were frequently elevated (median 9.95 kPa), and elevated LSM was associated with PHTN. All-cause mortality was higher in those with CVID-rLD (24/91, 26.4% vs. 14/127, 11%, p=0.003), which was the only organ complication associated with mortality (HR 2.24, 1.06-4.74, p=0.04). Factors predicting mortality in CVID-rLD included PHTN, increasing fibrosis, and LSM.

conclusionsLiver disease is a common complication of CVID as part of complex, multi-organ involvement and is associated with high rates of PHTN and an increased hazard of mortality.

Indexed as

Common Variable ImmunodeficiencyHypertension, PortalBiopsyFibrosisHumansRetrospective Studies

Identifiers

PMID38099861
PMCPMC10727572
OpenAlexW4389781886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.